Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2016 | May 16, 2016 | |
Document Information [Line Items] | ||
Entity Registrant Name | Amchi Gendynamy Science Corp | |
Entity Central Index Key | 1,610,764 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well-known Seasoned Issuer | No | |
Entity Common Stock, Shares Outstanding (in shares) | 247,207,994 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2016 | |
Document Fiscal Year Focus | 2,016 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | true | |
Amendment Description | The purpose of this Amendment to Form 10-Q ("Amendment") is to amend our initial filing of a Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016, filed with the Securities and Exchange Commission on May 16, 2016 (the "Initial Filing"), to reclassify $60,445 of Deposits previously categorized in the Statement of Cash Flows for the three months ended March 31, 2016 (Unaudited) in the Cash Flows From Operating Activities, to the Cash Flows From Financing Activities. This change also resulted in increase in general and administrative expenses by $45 to $46,216 and increase in a net loss to $46,191 for the three months ended March 31, 2016 (Unaudited). In addition, we revised Item IV "Controls and Procedures" section. Except with respect to the changes in the financial statements described above, and corresponding changes to the Management's Discussion and Analysis of Financial Condition and Results of Operations section of this report, and revising Item IV - Controls and Procedures, the Initial Filing has not been amended, updated or otherwise modified. Unless specified, the disclosures provided in this report have not been updated for more current information. Therefore, this Amendment should be read in conjunction with our other filings made with the Securities and Exchange Commission subsequent to the date of the Initial Filing. |
Balance Sheets (Current Period
Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2016 | Dec. 31, 2015 |
Current Assets | ||
Cash and cash equivalents | $ 515,106 | $ 59,837 |
Prepaid expense | 7,400 | |
Total Current Assets | 515,106 | 67,237 |
Other Assets | ||
Patent rights and trademark | 30,400 | 10,400 |
Total Assets | 545,506 | 77,637 |
Current Liabilities | ||
Accounts payable | 14,162 | 15,000 |
Payable to related party | 9,859 | 102,172 |
Deposits | 60,445 | |
Total Current Liabilities | 24,021 | 177,617 |
Total Liabilities | 24,021 | 177,617 |
Stockholders' Equity (Deficit) | ||
Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued and outstanding at March 31, 2016 and December 31, 2015, respectively | ||
Common stock, $0.0001 par value, 500,000,000 shares authorized; 247,207,994 shares and 20,500,000 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively | 24,721 | 2,050 |
Discount on common stock | (2,050) | (2,050) |
Additional paid in capital | 646,735 | 1,751 |
Deficit accumulated during development stage | (147,922) | (101,731) |
Total Stockholders' Equity (Deficit) | 521,484 | (99,980) |
Total Liabilities and Stockholders' Equity | $ 545,506 | $ 77,637 |
Balance Sheets (Current Period3
Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Mar. 31, 2016 | Dec. 31, 2015 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 20,000,000 | 20,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 500,000,000 | 500,000,000 |
Common stock, shares issued (in shares) | 247,207,994 | 20,500,000 |
Common stock, shares outstanding (in shares) | 247,207,994 | 20,500,000 |
Statements of Operations (Unaud
Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
Revenue | ||
Cost of Revenue | ||
Gross Profit | ||
Operating Expenses | ||
General and administrative | 46,216 | |
Total Operating Expenses | 46,216 | |
Operating Loss From Operations | (46,216) | |
Other Income (Expenses) | 25 | |
Loss From Operations Before Income Tax | (46,191) | |
Provision For Income Tax | ||
Net Loss | $ (46,191) | |
Basic and Diluted Net Loss Per Share (in dollars per share) | ||
Weighted Average Number of Shares Outstanding (in shares) | 186,543,204 | 20,000,000 |
Statements of Cash Flows (Unaud
Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2016 | Mar. 31, 2015 | |
Cash Flows from Operating Activities | ||
Net loss | $ (46,191) | |
Adjustment to reconcile net loss to net cash provided by operating activities: | ||
Expenses paid by stockholder and contributed as capital | ||
Changes in operating assets and liabilities | ||
Prepaid expense | 7,400 | |
Accounts payable | 837 | |
Net Cash Used in Operating Activities | (39,628) | |
Cash Flows from Investing Activities | ||
Cash Flows from Financing Activities | ||
Cash paid to related party against advances | (92,313) | |
Cash proceeds from sale of common stock | 587,210 | |
Net Cash Provided by Financing Activities | 494,897 | |
Net Increase in Cash and Cash Equivalents | 455,269 | |
Cash and Cash Equivalents, Beginning of the Period | 59,837 | |
Cash and Cash Equivalents, End of the Period | 515,106 | |
Supplemental Disclosures of Cash Flow Information | ||
Cash paid for income taxes | ||
Cash paid for interest | ||
Supplemental Disclosures of Non-Cash Investing and Financing Activities: | ||
Conversion of deposits received into issuance of common stock | 60,445 | |
Assignment of patent rights and trademark in exchange of common stock | $ 20,000 |
Note 1 - Nature of Operations a
Note 1 - Nature of Operations and Going Concern | 3 Months Ended |
Mar. 31, 2016 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | NOTE 1 – NATURE OF OPERATIONS AND GOING CONCERN As used herein and except as otherwise noted, the term “Company”, “it(s)”, “our”, “us”, “we” and “Amchi” shall mean Amchi Gendynamy Science Corporation, a Delaware corporation. A mchi Gendynamy Science Corporation, formerly known as Pretty Valley Acquisition Corporation, was incorporated on May 20, 2014 under the laws of the state of Delaware. On June 18, 2014, Pretty Valley Acquisition Corporation filed a registration statement with the Securities and Exchange Commission on Form 10 by which it became a public reporting company. In September, 2015, the Company implemented a change of control by redeeming shares of existing shareholders, issuing shares to new shareholders, electing new officers and directors and accepting the resignations of its then existing officers and directors. In connection with the change of control, the shareholders of the Company and its board of directors unanimously approved the change of the Company’s name from Pretty Valley Acquisition Corporation to Amchi Gendynamy Science Corporation. The Company has been formed to provide a method for a foreign or domestic private company to become a reporting company with a class of securities registered under the Securities Exchange Act of 1934. The Company is an early-stage development company using a special designed message machine along with acoustic wave to replace medicine and insulin to help diabetes patients to recovery from high blood sugar and medicine side effects. In China, Amchi is one of a few companies in the field of developing a physical method to treat Diabetes, utilizing electrical frequencies and special acoustic waves, which the founder of the Company has devoted many years in researching this Chinese traditional sound wave treatment. The Company has been working to determine what is the right multiple frequency, and how this frequency works on Diabetes to lower blood sugar. The Company’s research is in its early stages and there is no assurance that its therapy protocol or its energy devices will ever be able to be proved and accepted by the scientific and medical communities. Going Concern The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet generated any revenue and has sustained operating losses since inception to date and allow it to continue as a going concern. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary financing to continue operations, and the attainment of profitable operations. The Company incurred a net loss of $46,191 for the three months ended March 31, 2016, used net cash in operating activities of $39,628, had a working capital surplus of $491,085, and has an accumulated deficit of $147,922 as of March 31, 2016. These factors, among others raise a substantial doubt regarding the Company’s ability to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The accompanying financial statements do not include any adjustments to reflect the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2016 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following summary of significant accounting policies of the Company is presented to assist in the understanding of the Company’s financial statements. The financial statements and notes are the representation of the Company’s management who is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America ("GAAP") in all material respects, and have been consistently applied in preparing the accompanying financial statements. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates of valuation of equity instruments. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and on deposit at banking institutions. The Company did not have cash equivalents as of March 31, 2016 and December 31, 2015, respectively. Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company has the cash balances in excess of the Federal Deposit Insurance Corporation limit as of March 31, 2016 and not as of December 31, 2015. Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions Earnings (Loss) Per Common Share The Company computes net earnings (loss) per share in accordance with ASC 260, “ Earnings per Share” Fair value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts payable, payable to a related party and short term deposits. Pursuant to ASC 820 and ASC 825, “ Financial Instruments” Patents Rights and Trademark Patent rights and trademarks which are stated at cost, relate to the cost of applications submitted for obtaining patent and trademark of our Genome Repair Device, a non-invasive treatment device. Cost is based on third party expenditures for patent applications. We will begin amortizing our patent rights and trademark over their estimated remaining useful life when we begin revenue-producing activities. We will determine the useful lives of patent rights and trademark after considering the specific facts and circumstances related to each such asset. Factors we consider when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, our long-term strategy for using the asset, any laws or other local regulations that could impact the useful life of the asset, and other economic factors, including competition and specific market conditions. As of March 31, 2016 and December 31, 2015, the Company expended $30,400 and $10,400 in costs for submitting the application for patent rights and trademark which includes patent rights assigned by our Officer to the Company. New Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. |
Note 3 - Related Party Transact
Note 3 - Related Party Transactions | 3 Months Ended |
Mar. 31, 2016 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | NOTE 3 – RELATED PARTY TRANSACTIONS On September 16, 2015, Everrich Global Investments Limited (“Everrich”), an entity owned and controlled by Wisdom Qiao, the Chief Executive Officer of the Company (the “Officer”), entered into an agreement with Tiber Creek Corporation (“Tiber Creek”), an entity controlled by the founders of the Company, to exercise change in control of the Company. Upon the change in control of the Company, the existing shareholders of Tiber Creek retained 500,000 common shares of the Company and the remaining outstanding shares were returned to the Company. In full satisfaction of the services of Tiber Creek, Everrich agreed to pay a non-refundable consideration of $85,000 in legal and professional fees to Tiber Creek. The Officer has paid on behalf of the Company $80,000 of the consideration to Tiber Creek and the remaining $5,000 is recorded as accounts payable as of March 31, 2016. On January 26, 2016, the Company’s Board of Directors approved and ratified the assignment (the “Assignment”) by the Officer of her entire right, title and ownership interest in a patent application entitled “DYNAMIC RECOVERY AND THERAPY SYSTEM” (the “Invention”) in exchange for 200,000,000 shares of the Company’s common stock. Pursuant to the Assignment, on January 26, 2016, the Company issued 200,000,000 shares of its common stock to its Officer and valued them at $20,000 (Note 6). The transfer of nonmonetary asset by its Officer in exchange of common stock is recorded at the Officer’s historical cost basis determined under USGAAP. Since the common stock of the Company is closely held and not traded, estimating the fair value of the common stock issued is not appropriate. Therefore, upon the assignment of entire right, title and ownership interest in patent application by the Officer to the Company in exchange for 200,000,000 shares of the Company’s common stock, the Company valued the patent rights, title and ownership at its historical cost which approximated $20,000. The Officer has occasionally provided short term advances to the Company for opening its bank accounts and payments to vendors for performing services to the Company. The short term advances are non-interest bearing, unsecured and due on demand. For the three months ended March 31, 2016, the Company paid to the Officer $92,313 towards the advances provided for its working capital needs. The Company is indebted to the Officer $9,859 and $102,172 due and payable as of March 31, 2016 and December 31, 2015, respectively. |
Note 4 - Deposits
Note 4 - Deposits | 3 Months Ended |
Mar. 31, 2016 | |
Notes to Financial Statements | |
Deposits for Purchase of Common Shares [Text Block] | NOTE 4 – DEPOSITS As of March 31, 2016 and December 31, 2015, respectively, the Company had received cash deposits of $0 and $60,445 from two investors for purchase of common shares pursuant to a prospective private placement. The private placement for sale of common shares took place in January 2016, and such deposits received from two investors, were converted into equity, by issuance of 218,000 shares of common shares pursuant to the private placement as of March 31, 2016 (Note 6). |
Note 5 - Commitments and Contin
Note 5 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2016 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 5 – COMMITMENTS AND CONTINGENCIES Legal Costs and Contingencies In the normal course of business, the Company incurs costs to hire and retain external legal counsel to advise it on regulatory, litigation and other matters. The Company expenses these costs as the related services are received. On February 11, 2016, the Company entered into a Product Design Service Agreement with Focus Product Design, a California corporation, to design product requirements, systems architecture, proof of concept ME and EE, part sourcing, product architecture, etc. for a fixed fee of $635,100. The agreement will continue to be effective until performed by Focus. The Company had paid to Focus Product Design $7,400 towards the product design cost as of December 31, 2015 which was recorded as a prepaid expense. The cost of product design was expensed during the period ended March 31, 2016. If a loss is considered probable and the amount can be reasonable estimated, the Company recognizes an expense for the estimated loss. If the Company has the potential to recover a portion of the estimated loss from a third party, the Company makes a separate assessment of recoverability and reduces the estimated loss if recovery is also deemed probable. |
Note 6 - Stockholders' Equity
Note 6 - Stockholders' Equity | 3 Months Ended |
Mar. 31, 2016 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 6 – STOCKHOLDERS’ EQUITY The Company’s capitalization at March 31, 2016 was 500,000,000 authorized common shares with a par value of $0.0001 per share, and 20,000,000 authorized preferred shares with a par value of $0.0001 per share. Common stock On January 15, 2016, the Company completed a private placement of 26,707,994 shares of its common stock to 37 investors (the “Investors”) for a total purchase price of $647,655. All of the sales were made in China and all of the Investors were residents of China. The Company has issued the share certificates to all 37 investors as of March 31, 2016. All of the stock certificates issued to the Investors have been affixed with an appropriate legend restricting sales and transfers. Therefore, based on the foregoing, the Company has issued the shares in reliance upon the exemptions from registration provided by Section 4a (2) of the Securities Act of 1933 and/or Regulation S. On January 26, 2016, the Company’s Board of Directors approved and ratified the assignment (the “Assignment”) by Wisdom Qiao, the CEO, director and principal shareholder of the Company (“Officer”), of her entire right, title and interest in a patent application entitled “DYNAMIC RECOVERY AND THERAPY SYSTEM” (the “Invention”) in exchange for 200,000,000 shares of the Company’s common stock. Pursuant to the Assignment, on January 26, 2016, the Company issued to its Officer 200,000,000 shares of its common stock valued at $20,000 (Note 3). The shares are restricted and the certificates have been affixed with the appropriate legend restricting sales and transfers. As a result of all common stock issuances, the total outstanding shares of common stock at March 31, 2016 were 247,207,994. Preferred stock At March 31, 2016, the Company had no shares of preferred stock issued or outstanding. |
Note 7 - Subsequent Events
Note 7 - Subsequent Events | 3 Months Ended |
Mar. 31, 2016 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | NOTE 7 – SUBSEQUENT EVENTS The Company has evaluated subsequent events and transactions that occurred through the date and time our financial statements were issued for potential recognition or disclosure in the accompanying financial statements. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2016 | |
Accounting Policies [Abstract] | |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates of valuation of equity instruments. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents Cash and cash equivalents include cash on hand and on deposit at banking institutions. The Company did not have cash equivalents as of March 31, 2016 and December 31, 2015, respectively. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company has the cash balances in excess of the Federal Deposit Insurance Corporation limit as of March 31, 2016 and not as of December 31, 2015. |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions |
Earnings Per Share, Policy [Policy Text Block] | Earnings (Loss) Per Common Share The Company computes net earnings (loss) per share in accordance with ASC 260, “ Earnings per Share” |
Fair Value Measurement, Policy [Policy Text Block] | Fair value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts payable, payable to a related party and short term deposits. Pursuant to ASC 820 and ASC 825, “ Financial Instruments” |
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | Patents Rights and Trademark Patent rights and trademarks which are stated at cost, relate to the cost of applications submitted for obtaining patent and trademark of our Genome Repair Device, a non-invasive treatment device. Cost is based on third party expenditures for patent applications. We will begin amortizing our patent rights and trademark over their estimated remaining useful life when we begin revenue-producing activities. We will determine the useful lives of patent rights and trademark after considering the specific facts and circumstances related to each such asset. Factors we consider when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, our long-term strategy for using the asset, any laws or other local regulations that could impact the useful life of the asset, and other economic factors, including competition and specific market conditions. As of March 31, 2016 and December 31, 2015, the Company expended $30,400 and $10,400 in costs for submitting the application for patent rights and trademark which includes patent rights assigned by our Officer to the Company. |
New Accounting Pronouncements, Policy [Policy Text Block] | New Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. |
Note 1 - Nature of Operations14
Note 1 - Nature of Operations and Going Concern (Details Textual) - USD ($) | 3 Months Ended | ||
Mar. 31, 2016 | Mar. 31, 2015 | Dec. 31, 2015 | |
Net Income (Loss) Attributable to Parent | $ (46,191) | ||
Net Cash Provided by (Used in) Operating Activities, Continuing Operations | (39,628) | ||
Working Capital Surplus | 491,085 | ||
Retained Earnings (Accumulated Deficit) | $ (147,922) | $ (101,731) |
Note 2 - Summary of Significa15
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2016 | Dec. 31, 2015 | |
Patents and Trademarks [Member] | ||
Finite-Lived Intangible Assets, Net | $ 30,400 | $ 10,400 |
Cash Equivalents, at Carrying Value | $ 0 | $ 0 |
Weighted Average Number Diluted Shares Outstanding Adjustment | 0 | 0 |
Cash, Uninsured Amount | $ 0 | |
Finite-Lived Intangible Assets, Net | $ 30,400 | $ 10,400 |
Note 3 - Related Party Transa16
Note 3 - Related Party Transactions (Details Textual) - USD ($) | Jan. 26, 2016 | Mar. 31, 2016 | Mar. 31, 2015 | Dec. 31, 2015 | Sep. 16, 2015 |
Tiber Creek [Member] | Legal and Professional Fees, Non-refundable [Member] | |||||
Operating Expenses | $ 85,000 | ||||
Related Party Transaction, Amounts of Transaction | 80,000 | ||||
Accounts Payable, Related Parties, Current | 5,000 | ||||
Tiber Creek [Member] | |||||
Common Stock, Retain, Upon the Change in Control of the Company | $ 500,000 | ||||
Common Stock Exchange for Patent Application [Member] | Chief Executive Officer [Member] | |||||
Stock Issued During Period, Shares, New Issues | 200,000,000 | ||||
Chief Executive Officer [Member] | |||||
Stock Issued During Period, Shares, New Issues | 200,000,000 | ||||
Stock Issued During Period, Value, New Issues | $ 20,000 | ||||
Officer [Member] | |||||
Accounts Payable, Related Parties, Current | 9,859 | $ 102,172 | |||
Repayments of Related Party Debt | 92,313 | ||||
Operating Expenses | 46,216 | ||||
Accounts Payable, Related Parties, Current | $ 9,859 | $ 102,172 |
Note 4 - Deposits (Details Text
Note 4 - Deposits (Details Textual) | Jan. 15, 2016shares | Mar. 31, 2016USD ($)shares | Dec. 31, 2015USD ($) |
Private Placement [Member] | |||
Number of Investors | 37 | 2 | |
Sale of Stock, Number of Shares Issued in Transaction | shares | 26,707,994 | 218,000 | |
Deposits, Purchase of Common Shares, Prospective Private Placement | $ | $ 0 | $ 60,445 |
Note 5 - Commitments and Cont18
Note 5 - Commitments and Contingencies (Details Textual) - USD ($) | Feb. 11, 2016 | Mar. 31, 2016 | Dec. 31, 2015 |
Focus Product Design [Member] | |||
Prepaid Expense, Current | $ 7,400 | ||
Product Design Fixed Service Fee | $ 635,100 | ||
Prepaid Expense, Current | $ 7,400 |
Note 6 - Stockholders' Equity (
Note 6 - Stockholders' Equity (Details Textual) | Jan. 26, 2016USD ($)shares | Jan. 15, 2016USD ($)shares | Mar. 31, 2016$ / sharesshares | Dec. 31, 2015$ / sharesshares |
Private Placement [Member] | ||||
Sale of Stock, Number of Shares Issued in Transaction | 26,707,994 | 218,000 | ||
Number of Investors | 37 | 2 | ||
Sale of Stock, Consideration Received on Transaction | $ | $ 647,655 | |||
Common Stock Exchange for Patent Application [Member] | Chief Executive Officer [Member] | ||||
Stock Issued During Period, Shares, New Issues | 200,000,000 | |||
Chief Executive Officer [Member] | ||||
Stock Issued During Period, Shares, New Issues | 200,000,000 | |||
Stock Issued During Period, Value, New Issues | $ | $ 20,000 | |||
Preferred Stock, Shares Issued | 0 | 0 | ||
Preferred Stock, Shares Outstanding | 0 | 0 | ||
Common Stock, Shares Authorized | 500,000,000 | 500,000,000 | ||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | $ 0.0001 | ||
Preferred Stock, Shares Authorized | 20,000,000 | 20,000,000 | ||
Preferred Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | $ 0.0001 | ||
Common Stock, Shares, Outstanding | 247,207,994 | 20,500,000 |